| 產(chǎn)品編號 | BIO0262SM |
| 英文名稱(chēng) | Anti-human SIRPa / CD172a (Hospital for Sick Children patent Anti-SIRPA Biosimilar) |
| 中文名稱(chēng) | |
| 抗體來(lái)源 | |
| 克隆類(lèi)型 | Monoclonal |
| 克 隆 號 | |
| 交叉反應 | Human |
| 產(chǎn)品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 145 kDa |
| 檢測分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG4SP |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Hospital for Sick Children patent anti-SIRPA FACS Blocking was evaluated using human CCRF-CEM cells. The IC50 was approximately 3.289 ug/ml.
nM.
Immobilized human SIRPα V1 FC at 4 ug/mL can bind Hospital for Sick Children patent anti-SIRPA, EC50=0.007292 ug/mL.
The purity of Anti-SIRPa / CD172a Reference Antibody (Hospital for Sick Children patent anti-SIRPA) is more than 95%, determined by SEC-HPLC.
Anti-SIRPa / CD172a Reference Antibody (Hospital for Sick Children patent anti-SIRPA) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
